what is PT-141?
bremelanotide, the on-demand MC4R agonist sold as Vyleesi -- the only FDA-approved peptide medication for HSDD in premenopausal women
a cyclic heptapeptide medication for a defined sexual-health condition
PT-141 -- the chemistry name is bremelanotide and the US brand name is Vyleesi -- is a synthetic cyclic 7-amino-acid peptide that activates the melanocortin-4 receptor (MC4R) in the brain. The FDA approved it in June 2019 for one narrow indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is given as a single 1.75 mg subcutaneous injection on demand, taken at least 45 minutes before anticipated sexual activity (Kingsberg et al. 2019; Dhillon and Keam 2019; FDA 2019).
PT-141 sits in an unusual category for a peptide on this site. Most of the molecules in the curriculum live in the research-chemical or compounded-pharmacy space. Vyleesi is a regulated prescription medication with replicated Phase 3 trial data, a defined label population, and a specific clinical use case. It is on-demand, not daily; it is medical, not biohacker; and the rest of this course treats it that way. Off-label use in men, in postmenopausal women, and in recreational contexts is real and is covered in unit 8, but the central frame is the FDA-approved indication for which it is the only on-demand peptide in the entire melanocortin class.
PT-141 in plain terms
a synthetic peptide medication for a defined sexual-health disorder, with a narrow indication and a specific mechanism that distinguishes it from every other approved sexual-function drug.
a drug for one disorder, not a general libido pill
Vyleesi is approved for HSDD in premenopausal women. HSDD is a specific clinical diagnosis -- absence or deficiency of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, not better accounted for by another condition or medication. The word "acquired" means the condition is not lifelong; the word "generalized" means it is not partner- or situation-specific. PT-141 was never developed as a general libido enhancer, and the label is deliberately narrow (Kingsberg et al. 2019; Dhillon and Keam 2019).
why HSDD needs a central drug
The standard-of-care drugs for male erectile dysfunction -- sildenafil (Viagra), tadalafil (Cialis), and the rest of the PDE5 inhibitor class -- work on penile blood flow. They block an enzyme called phosphodiesterase-5 so that nitric-oxide-driven vasodilation lasts longer in the corpus cavernosum. They require existing sexual stimulation; they are erection enablers, not desire creators. None of that biology helps with a disorder of desire, where the upstream motivational signal is the problem. PT-141 was developed specifically because HSDD lives upstream of the vascular machinery, in the hypothalamic and limbic circuits that integrate motivation, arousal, and autonomic outflow (Pfaus et al. 2022; Molinoff et al. 2003).
on-demand, not daily
This is the single most important framing to get right: Vyleesi is taken episodically, not on a schedule. A user injects 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity. The label caps usage at one dose in any 24-hour window and at eight doses across any 30-day period. That cap is partly a safety throttle for blood pressure and cumulative-dose hyperpigmentation (covered below) and partly an implicit assumption that the drug is for occasional use. Framing PT-141 as "a peptide you take daily for wellness" misses the entire approved use case (Vyleesi label; Kingsberg et al. 2019).
key terms
definitions for the technical words that show up across this course. tap to expand.
interactive: PT-141 vs PDE5 inhibitor
tap each pathway to see how a central MC4R agonist and a peripheral PDE5 inhibitor address sexual dysfunction at different parts of the circuit. the takeaway is that the two drug classes are not interchangeable -- they target different layers of the same biology.
tap a node in either pathway to see how that step contributes to sexual response, and whether PT-141, a PDE5 inhibitor, or neither acts there
central MC4R vs peripheral PDE5
the single most important mechanistic distinction in this course -- and the misconception PT-141 marketing most often glosses over.
two drug classes, two parts of the body
The textbook way to teach sexual response is as a sequence: desire arises in the brain, arousal recruits autonomic outflow, vascular changes produce erection or genital engorgement, and the cycle plays out from there. PDE5 inhibitors act in the third step. They prolong nitric-oxide-driven cGMP signaling in penile vascular smooth muscle. They require an upstream desire and arousal signal to do anything; without it, the corpus cavernosum is not relaxing in the first place.
PT-141 acts in the first step. It engages MC4R in the hypothalamic paraventricular nucleus and medial preoptic area -- the central hubs that integrate sexual motivation. Downstream, this raises oxytocinergic and dopaminergic tone in the sexual-reward circuitry. The behavioral output is increased desire and arousal; the vascular response follows naturally from the autonomic outflow that desire engages (Pfaus et al. 2022; Van der Ploeg et al. 2002; Molinoff et al. 2003).
why the distinction matters clinically
PT-141 (central)
Engages hypothalamic MC4R. Raises oxytocin and dopamine tone in sexual-circuit hubs. Facilitates desire and arousal upstream of any vascular event.
Works in populations where the upstream signal is the problem: HSDD in women, psychogenic ED, and PDE5-inadequate ED in men. The vascular machinery is normal; what is missing is the upstream go-signal.
PDE5 inhibitors (peripheral)
Block phosphodiesterase-5 in penile vascular smooth muscle. Prolong cGMP-mediated vasodilation in response to nitric-oxide signaling from cavernous nerves.
Works only when the upstream signal is intact. If desire and arousal are absent, nothing happens. This is why PDE5 inhibitors fail in HSDD and in "PDE5-inadequate" male ED.
complementary, not redundant
The reason this matters in practice: the two drug classes are mechanistically complementary, not redundant. In men with PDE5-inadequate response, the older Diamond 2005 intranasal Phase 2 study showed enhanced erectile response when low-dose intranasal PT-141 was co-administered with low-dose sildenafil (Diamond et al. 2005). The signal was additive: a central go-signal plus peripheral vasodilation. The combination has not been re-studied in the modern Vyleesi-approved era, but the mechanistic logic remains.
Vyleesi and the HSDD indication
why the FDA approval is narrow on purpose, and what RECONNECT actually showed.
June 21, 2019: a narrow approval
The FDA approved bremelanotide on June 21, 2019 with a deliberately narrow label: acquired, generalized HSDD in premenopausal women. The agency did not extend the approval to postmenopausal women (no Phase 3 trial in that population), to men (the male ED program had been halted in 2008), or to general libido enhancement (the trials never tested that). The narrow label reflects an honest match between the evidence base and the indication (FDA 2019; Dhillon and Keam 2019; Kingsberg et al. 2019).
RECONNECT: the supporting evidence
Two pre-specified Phase 3 trials supported approval: Study 301 and Study 302, collectively the RECONNECT program. They were identically designed: double-blind, placebo-controlled, parallel-group, multicenter. Combined randomized population was 1,267 premenopausal women with acquired, generalized HSDD. Treatment was 1.75 mg subcutaneous on demand vs matching placebo. Duration was 24 weeks double-blind followed by a 52-week open-label safety extension (Kingsberg et al. 2019; Simon et al. 2019).
the co-primary endpoints
RECONNECT used two co-primary endpoints, both patient-reported. FSFI-Desire measures self-reported sexual desire on the validated Female Sexual Function Index Desire domain (1.2-6.0 scale). FSDS-DAO Item 13 measures self-reported distress about low desire on a 0-4 scale. Both endpoints improved meaningfully more with bremelanotide than with placebo, and the difference reached statistical significance in both trials.
safety snapshot: BP and hyperpigmentation
two safety signals that PT-141 marketing routinely buries. unit 7 is dedicated to the full safety profile; this is the highlight reel.
transient blood pressure elevation
Bremelanotide causes a transient rise in blood pressure 2-4 hours after each dose. The signal is consistent across the dedicated White 2017 ambulatory blood pressure monitoring study and the RECONNECT pivotal trials. Mean increase is approximately +6 mmHg systolic and +3 mmHg diastolic, with a roughly 5 bpm decrease in heart rate, returning to baseline within 8-12 hours. The mechanism is presumed sympathetic, mediated by melanocortin agonism in autonomic brainstem centers (White et al. 2017; Kingsberg et al. 2019).
focal hyperpigmentation
Roughly 1% of subjects in RECONNECT developed focal hyperpigmentation -- darker patches of skin or gum tissue, most commonly gingival, facial (especially nose and cheeks), or breast. The mechanism is residual MC1R agonism in skin melanocytes driving melanogenesis. Crucially, the pigment is not reliably reversible: once melanocytes are committed to a higher melanin program, the change can persist after the drug is stopped. Risk rises with cumulative dose count, which is part of the rationale for the 8-doses-per-30-day label cap (Kingsberg et al. 2019; Simon et al. 2019).
honest evidence ceiling
what is solid, what is suggestive, and what is anecdotal in the PT-141 evidence base.
premenopausal HSDD
Replicated Phase 3 RCT data plus a 52-week open-label extension supporting the FDA approval.
- RECONNECT Studies 301 and 302 enrolled 1,267 premenopausal women with acquired, generalized HSDD (Kingsberg et al. 2019).
- both co-primary endpoints (FSFI-Desire, FSDS-DAO Item 13) reached statistical significance over placebo.
- 52-week open-label extension showed persistent efficacy without new cardiovascular safety signal (Simon et al. 2019).
central CNS mechanism
Cross-validated by genetic knockouts, preclinical neurobiology, and human fMRI.
- MC4R knockout mice show reduced sexual function; MC4R agonists rescue it (Huszar et al. 1997; Van der Ploeg et al. 2002).
- female rat studies show selective facilitation of appetitive sexual behaviors (Pfaus et al. 2004).
- fMRI in women with HSDD shows enhanced limbic and prefrontal activation to erotic stimuli on bremelanotide (Thurston et al. 2022).
off-label male ED
Older intranasal Phase 2 data plus mechanistic extrapolation.
- Diamond 2004 and Rosen 2004 documented dose-related erectile response to intranasal PT-141 (Diamond et al. 2004; Rosen et al. 2004).
- Diamond 2005 showed additive response with low-dose sildenafil co-administration (Diamond et al. 2005).
- the intranasal program was halted in 2008 due to BP signal at higher doses; no modern subcutaneous Phase 3 has been completed in men.
postmenopausal HSDD and recreational use
The label specifically excludes postmenopausal women, and recreational use has no controlled data.
- no Phase 3 trial in postmenopausal HSDD has been completed -- the population was excluded from RECONNECT.
- community recreational use ("general libido peptide") lacks controlled trial data in either sex.
- long-term safety data beyond 76 weeks of approved-product use have not been published.
what you will learn
where this course goes from here.
The next ten units take this unit's overview and go much deeper, each one earning the "mastery" label by a different kind of depth. Unit 2 grounds you in the melanocortin receptor system. Unit 3 dissects the cyclic heptapeptide chemistry. Unit 5 walks through the RECONNECT program in detail. Unit 7 is the dedicated safety unit with a full treatment of the BP signal, the hyperpigmentation risk, and the naltrexone interaction.
-
02
the melanocortin receptor system
POMC processing, the five MC receptors, MC4R's distribution across the hypothalamus and limbic system, and why MC4R is the libido receptor.
-
03
cyclic heptapeptide chemistry
the Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH sequence, the Asp-Lys lactam bridge, and the single C-terminal edit that distinguishes PT-141 from melanotan II.
-
04
CNS mechanism: hypothalamic MC4R
how MC4R engagement raises oxytocin and dopamine tone, what fMRI evidence shows, and why one drug helps desire in women and erection in men.
-
05
the RECONNECT Phase 3 program
the marquee evidence unit. Clayton 2016 Phase 2b, Studies 301 and 302 design, FSFI-Desire and FSDS-DAO Item 13, and the satisfying-event miss.
-
06
dosing and administration
1.75 mg subcutaneous on demand, ≥45 min before activity, the 8-doses-per-30-day cap, autoinjector technique, and the discontinued intranasal route.
-
07
safety: BP, nausea, hyperpigmentation
the focus unit. transient ~6/3 mmHg BP rise, ~40% nausea, focal hyperpigmentation, the oral naltrexone interaction, and cardiovascular contraindications.
-
08
off-label male erectile dysfunction
the Wessells 1998 MT-II signal, the intranasal Phase 2 program (Diamond 2004, Rosen 2004), the sildenafil combination data, and the modern Phase 3 gap.
-
09
PT-141 vs melanotan II
same cyclic heptapeptide family, single C-terminal edit, different receptor bias, different intended use. how the catalog keeps the two distinct.
-
10
regulatory, access, and cost
FDA 2019 approval, EMA application withdrawn, WADA non-prohibited status, compounding pharmacy reality, and Vyleesi cost vs gray-market PT-141.
-
11
final exam and certification
comprehensive exam covering all ten prior units. pass and earn a PT-141 Specialist certificate.
By the end you should be able to read a prescribing-information sheet, a Reddit post, or a vendor page about PT-141 and immediately tell which claims trace to RECONNECT, which trace to older intranasal Phase 2 data, and which are extrapolation or marketing.
Knowledge Check
confirm the PT-141 identity, the HSDD framing, the central-vs-peripheral mechanism, and the visible safety signals before moving deeper.
Practice
reinforce the distinctions that matter most for the rest of the course.